Inhibrx PE Ratio 2020-2022 | INBX

Current and historical p/e ratio for Inhibrx (INBX) from 2020 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Inhibrx PE ratio as of May 27, 2022 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Inhibrx PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-05-27 13.65 0.00
2022-03-31 22.28 $-2.44 0.00
2021-12-31 43.67 $-2.15 0.00
2021-09-30 33.31 $-2.07 0.00
2021-06-30 27.52 $-2.30 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.533B $0.007B
Inhibrx Inc. is a clinical-stage biotechnology company. The company's pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00